• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Shire, Foundation Fighting Blindness ink research agreement for rare pediatric eye disease

Shire, Foundation Fighting Blindness ink research agreement for rare pediatric eye disease

May 4, 2015
CenterWatch Staff

Shire and the Foundation Fighting Blindness, a national nonprofit organization focused on the entire spectrum of retinal diseases, have formed a new agreement to further research for a novel treatment for autosomal dominant retinitis pigmentosa (adRP), a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There currently are no approved treatment options for adRP.

The Foundation Fighting Blindness and its research partners will provide Shire with knowledge and scientific background regarding adRP, as well as pertinent clinical information that could be useful in the development of a drug to treat adRP. Backed by its scientific advisory board, the Foundation Fighting Blindness also will provide counsel as requested on the preclinical and/or clinical development of Shire compounds in development for the treatment of adRP.

"Autosomal dominant retinitis pigmentosa is a rare, inherited disease that has a significant impact on patients and their families as they navigate the challenges associated with severe vision loss," said Patricia Zilliox, chief drug development officer, Foundation Fighting Blindness Clinical Research Institute. "Through our agreement with Shire, we are excited to drive R&D and extend our expertise to dedicated partners working to accelerate treatments for those living with retinal diseases."

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing